ALISO VIEJO, Calif., Aug. 23 /PRNewswire-FirstCall/ -- Clarient, Inc. , a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it has released its next-generation of PATHSiTE, an internet-based flow cytometry program that enables pathologists, when evaluating their leukemia and lymphoma cases, to have complete control over the gating analysis on cell populations. Clarient launched its upgraded online tool through its partnership with De Novo Software, the premier provider of Flow Cytometry Data Analysis Solutions.
“Through a long standing partnership, Clarient and De Novo Software have implemented a novel approach to performing ‘virtual flow cytometry analysis,’” said Kenneth Bloom, M.D., Chief Medical Officer at Clarient. “Flow cytometry analysis continues to be an integral technology platform for the care of cancer patients. Unfortunately, due to a variety of factors, many major hospitals and labs throughout the U.S. do not have access to flow cytometry technology. Over the years, Clarient has continued to collaborate with these facilities by extending our flow cytometry capabilities through a virtual laboratory, empowering our pathologist clients to perform additional analysis on their flow cytometry cases, right from their own office.”
Today’s launch positions Clarient as one of the first labs in the United States to offer its clients the ability to interact with their flow cytometry analysis and to perform gating and regating analysis, as necessary, at a remote location. Proper gating is a critical initial step in the data analysis and interpretation of flow cytometry cases.
De Novo Software is one of the premier providers of flow cytometry data analysis solutions. By partnering with them, Clarient has integrated a version of FCS Express, the widely used and FDA registered software package, into PATHSiTE, allowing clients to download the flow analysis from Clarient’s web-based portal and modify the analysis as needed. This feature will help pathologists follow patients through the course of their disease pre- and post-treatment in a more efficient and effective manner.
Flow cytometry is a well recognized tool in the management of serious cancers such as hematopoietic and lymphoid malignancies. Over the past decade it has become a powerful tool in cancer diagnostics and therapeutic monitoring. The PATHSiTE web-based portal connects pathologists from around the U.S. to Clarient’s flow cytometry expertise as well as the instrumentation and software technology needed to effectively analyze specimen data.
Clarient’s President and CEO Ron Andrews said, “The annual flow cytometry market related to cancer testing in the U.S. is estimated by industry analysts to be valued over $600 million. Our continued investment in our PATHSiTE offering demonstrates our commitment to partner with pathologists nationwide through our virtual labs. We currently service a large base of hematopathology clients, and we want to ensure that we continue to collaborate with them to help meet their daily diagnostic challenges. Clarient’s continued ability to put more tools into the hands of the community pathologist allows us to provide higher levels of diagnostic service to our clients in an increasingly complex patient care environment.”
About Clarient
Clarient combines innovative technologies with world class expertise to assess and characterize cancer. Clarient’s mission is to provide the services, resources and critical information to improve the quality and reduce the cost of patient care as well as accelerating the drug development process. The Company’s principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies.
The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and drug development services available both onsite and over the web. Clarient is a Safeguard Scientifics, Inc. partner company. For more information, visit http://www.clarientinc.com.
About Safeguard
Safeguard Scientifics, Inc. , a holding company, builds value in growth-stage technology and life sciences businesses. Safeguard provides growth capital as well as a range of strategic, operating and management resources to our partner companies. Safeguard participates in growth buyout financings, including corporate spin-outs and management buyouts, expansion financings, industry consolidations and early-stage financings. http://www.safeguard.com
About De Novo Software
De Novo Software provides integrated solutions for the life sciences, primarily in the field of flow cytometry data analysis. Its primary product, FCS Express, is used by over one thousand laboratories worldwide for research purposes, and dozens of clinical laboratories for high throughput clinical analysis. As the only third-party flow analysis software registered with the FDA for in-vitro diagnostic use, FCS Express is the analysis tool of choice for the clinical laboratory. In addition, De Novo Software has extensive experience creating custom data analysis solutions and integrating with large scale LIS and HIS systems. For more information, please visit http://www.denovosoftware.com.
The statements herein regarding Clarient, Inc. contain forward-looking statements that involve risks and uncertainty. Future events and the Company’s actual results could differ materially from the results reflected in these forward-looking statements. Factors that might cause such a difference include, but are not limited to: the Company’s ability to successfully implement the upgrades to its PATHSiTE flow cytometry program described above, the acceptance of the Company’s PATHSiTE flow cytometry program in the marketplace, the Company’s ability to continue to develop and expand its diagnostic services business, the Company’s ability to expand and maintain a successful sales and marketing organization, the Company’s ability to maintain compliance with financial and other covenants under its credit facilities, the Company’s ability to successfully complete a joint development agreement with Zeiss for the development of novel diagnostic tests, whether the conditions to payment of all or any portion of the contingent consideration from the Company’s sale of its instrument systems business are satisfied, the continuation of favorable third party payer reimbursement for laboratory tests, the Company’s ability to obtain additional financing on acceptable terms or at all , unanticipated expenses or liabilities or other adverse events affecting cash flow, uncertainty of success in identifying and developing new diagnostic tests or novel markers, failure to obtain FDA clearance or approval for particular applications, the Company’s ability to compete with other technologies and with emerging competitors in novel cancer diagnostics and dependence on third parties for collaboration in developing new tests, and risks detailed from time to time in the Company’s SEC reports, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. Recent experience with respect to laboratory services, revenues and results of operations may not be indicative of future results for the reasons set forth above.
The company does not assume any obligation to update any forward-looking statements or other information contained in this document.
Contact: Matt Clawson John Baldissera Allen & Caron, Inc. BPC Financial Marketing (949) 474-4300 (800) 368-1217 matt@allencaron.com
Clarient, Inc.
CONTACT: Matt Clawson of Allen & Caron, Inc., +1-949-474-4300,matt@allencaron.com, or John Baldissera of BPC Financial Marketing,1-800-368-1217, both for Clarient, Inc.
